Copy Number-low/TP53-mutated Endometrial Cancer With Wild-type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next-generation Sequencing for Molecular Classification.

Published 04/21/2026

Research record: Copy Number-low/TP53-mutated Endometrial Cancer With Wild-type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next-generation Sequencing for Molecular Classification.

Published in Mod Pathol; first publication date 2026-04-21. PMID 42025847.

This literature update records publication metadata from Europe PMC. Consult the original publication for its methods, findings and limitations.

Read the original publication on PubMed

Talk to a Specialist Browse all insights

Review and references

Source

Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.

Published

2026-04-21

Updated

2026-10-20

Disclaimer

professional use

References